Event Abstract

Genetic variation in DNA repair genes: ERCC4 and XRCC3 and cervical squamous cell carcinoma risk

  • 1 Institute of Immunology & Experimental Therapy, Experimental Therapy, Poland
  • 2 EuroMedic Poland, International Oncological Center, Poland
  • 3 Medical University, Department of Oncology and Gynaecological Oncology Clinic, Poland

As reduced DNA repair capacity may lead to genetic instability and carcinogenesis, genes involved in DNA repair have been proposed as candidate cancer susceptibility genes including in cervical cancer.
ERCC4 (XPF) is one of central players in the NER, which counteracts the consequences of mutagenic exposure of cell. XRCC3 is known to participate in homologous recombination to maintain chromosome stability and repair DNA damage.
We investigated 4 tagSNPs in 2 DNA repair genes - ERCC4: rs3136176, rs1799798 and XRCC3: rs3212079, rs3212102 in 132 cervical squamous cell carcinoma (CSCC) patients and 196 healthy controls.
In single SNP analyses, we found that among studied SNPs 3 were directly associated with risk of CSCC: ERCC4rs3136176 and in XRCC3: rs3212079, rs3212102. With respect to ERCC4 SNP, we found that carriers of [TT] genotype was 2.82 more prone to CSCC (p=0.01, 95%CI:1.21-6.59).
With respect to XRCC3 SNPs, presence of rs3212102[CC] genotype 2.18 increased risk of cancer (p=0.04, 95%CI:1.03-4.65) and rs3212079[A] allele (genotype [AA] and/or [GA]) 2.37 increased risk of CSCC (p=0.006, 95%CI:1.27-4.42).
Haplotype XRCC3rs3212079[A]/XRCC3rs3212102[C] significantly increased risk of CSCC (p=0.0007).
Using multivariate logistic regression analysis, 3 of the investigated SNPs: ERCC4rs3136176, XRCC3rs3212079 and XRCC3rs3212102 showed a significant association with CSCC risk in the over all population.
Moreover, haplotype XRCC3rs3212079[A]/XRCC3rs3212102[C] showed a tendency to be more frequent in patients with carcimona planoepitheliale akeratodes (Cpa) as compared with keratodes type (Cpk) (p=0.07) and haplotype XRCC3rs3212079[G]/XRCC3rs3212102[C] showed an opposite tendency (p=0.07). None of studied SNPs were associated with grading or staging.

References

Liu P., Siciliano J., White B., Legerski R., Callen D., Reeders S., Siciliano M.J., Thompson L.H., Regional mapping of human DNA excision repair gene ERCC4 to chromosome 16p13.13-p13.2. Mutagenesis 1993, 8:199-205.
Brookman K.W., Lamerdin J.E., Thelen M.P., Hwang M., Reardon J.T., Sancar A., Zhou Z.Q., Walter C.A., Parris C.N., Thompson L.H., ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs. Mol Cell Biol 1996, 16:6553-656.
Brenneman M.A., Wagener B.M., Miller C.A., Allen C., Nickoloff J.A., XRCC3 Controls the Fidelity of Homologous Recombination: Roles for XRCC3 in Late Stages of Recombination. Mol Cell 2002, 10:387-395.
Goode E.L., Ulrich C.M., Potter J.D., Polymorphisms in DNA repair genes and associations with cancer risk. Can Epidemiol Biom Prev 2002, 11:1513-1530.
de Ryuck K., He X., Ye F., Zhang J., Cheng Q., Shen J., Chen H., Susceptibility of XRCC3, XPD, and XPG genetic variants to cervical carcinoma. Pathobiology 2008, 75:356-63.
de Ruyck K., van Eijkeren M., Claes K., Morthier R., de Paepe A., Vral A., de Rrider L., Thierens H., Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiation Oncology Biology Physics 2005, 62:1140–1149.

Keywords: CSCC, Polymorphism, Single Nucleotide, Genetic Predisposition to Disease, Cancer, DNA repair gene

Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.

Presentation Type: Abstract

Topic: Immune-mediated disease pathogenesis

Citation: Pawlak-Adamska EA, Bartosinska M, Wlodarska-Polinska I, Ignatowicz-Pacyna A, Kornafel J and Frydecka I (2013). Genetic variation in DNA repair genes: ERCC4 and XRCC3 and cervical squamous cell carcinoma risk. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00636

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 13 Jun 2013; Published Online: 22 Aug 2013.

* Correspondence: Dr. Edyta A Pawlak-Adamska, Institute of Immunology & Experimental Therapy, Experimental Therapy, Wroclaw, Lower Silesia, 53-114, Poland, edyta.pawlak@hirszfeld.pl